Literature DB >> 20414586

Occupational therapy in spinocerebellar ataxia type 3: an open-label trial.

R C R Silva1, J A M Saute, A C F Silva, A C O Coutinho, M L Saraiva-Pereira, L B Jardim.   

Abstract

Occupational therapy (OT) is a profession concerned with promoting health and well-being through occupation, by enabling handicapped people to participate in the activities of everyday life. OT is part of the clinical rehabilitation of progressive genetic neurodegenerative diseases such as spinocerebellar ataxias; however, its effects have never been determined in these diseases. Our aim was to investigate the effect of OT on both physical disabilities and depressive symptoms of spinocerebellar ataxia type 3 (SCA3) patients. Genomically diagnosed SCA3 patients older than 18 years were invited to participate in the study. Disability, as evaluated by functional independence measurement and Barthel incapacitation score, Hamilton Rating Scale for Depression, and World Health Organization Quality of Life questionnaire (WHOQOL-BREF), was determined at baseline and after 3 and 6 months of treatment. Twenty-six patients agreed to participate in the study. All were treated because OT prevents blinding of a control group. Fifteen sessions of rehabilitative OT were applied over a period of 6 months. Difficult access to food, clothing, personal hygiene, and leisure were some of the main disabilities focused by these patients. After this treatment, disability scores and quality of life were stable, and the Hamilton scores for depression improved. Since no medication was started up to 6 months before or during OT, this improvement was related to our intervention. No association was found between these endpoints and a CAG tract of the MJD1 gene (CAGn), age, age of onset, or neurological scores at baseline (Spearman test). Although the possibly temporary stabilization of the downhill disabilities as an effect of OT remains to be established, its clear effect on depressive symptoms confirms the recommendation of OT to any patient with SCA3 or spinocerebellar ataxia.

Entities:  

Mesh:

Year:  2010        PMID: 20414586     DOI: 10.1590/s0100-879x2010005000009

Source DB:  PubMed          Journal:  Braz J Med Biol Res        ISSN: 0100-879X            Impact factor:   2.590


  12 in total

1.  Occupational therapy intervention to inspire self-efficacy in a patient with spinal ataxia and visual disturbance.

Authors:  Satsuki Tohyama; Fusako Usuki
Journal:  BMJ Case Rep       Date:  2015-02-09

Review 2.  Spinocerebellar ataxias: prospects and challenges for therapy development.

Authors:  Tetsuo Ashizawa; Gülin Öz; Henry L Paulson
Journal:  Nat Rev Neurol       Date:  2018-10       Impact factor: 42.937

3.  Depressive mood is associated with ataxic and non-ataxic neurological dysfunction in SCA3 patients.

Authors:  Jonas Alex Morales Saute; Andrew Chaves Feitosa da Silva; Karina Carvalho Donis; Leonardo Vedolin; Maria Luiza Saraiva-Pereira; Laura Bannach Jardim
Journal:  Cerebellum       Date:  2010-12       Impact factor: 3.847

4.  Psychiatric disorders, spinocerebellar ataxia type 3 and CAG expansion.

Authors:  Uanda Cristina Almeida Silva; Wilson Marques; Charles Marques Lourenço; Jaime Eduardo C Hallak; Flávia L Osório
Journal:  J Neurol       Date:  2015-06-13       Impact factor: 4.849

Review 5.  The effectiveness of allied health care in patients with ataxia: a systematic review.

Authors:  Ella M R Fonteyn; Samyra H J Keus; Carla C P Verstappen; Ludger Schöls; Imelda J M de Groot; Bart P C van de Warrenburg
Journal:  J Neurol       Date:  2013-04-16       Impact factor: 4.849

6.  Effects of Physical Rehabilitation in Patients with Spinocerebellar Ataxia Type 7.

Authors:  Karla Tercero-Pérez; Hernán Cortés; Yessica Torres-Ramos; Roberto Rodríguez-Labrada; César M Cerecedo-Zapata; Oscar Hernández-Hernández; Nelson Pérez-González; Rigoberto González-Piña; Norberto Leyva-García; Bulmaro Cisneros; Luis Velázquez-Pérez; Jonathan J Magaña
Journal:  Cerebellum       Date:  2019-06       Impact factor: 3.847

7.  Fragile x-associated tremor ataxia syndrome: the expanding clinical picture, pathophysiology, epidemiology, and update on treatment.

Authors:  Deborah A Hall; Joan A O'keefe
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2012-05-11

8.  What is the best way to keep walking and moving around for individuals with Machado-Joseph disease? A scoping review through the lens of Aboriginal families with Machado-Joseph disease in the Top End of Australia.

Authors:  Jennifer J Carr; Joyce Lalara; Gayangwa Lalara; Moira Smith; Jennifer Quaill; Alan R Clough; Anne Lowell; Ruth N Barker
Journal:  BMJ Open       Date:  2019-09-30       Impact factor: 2.692

9.  Quality of Life since Pre-Ataxic Phases of Spinocerebellar Ataxia Type 3/Machado-Joseph Disease.

Authors:  Gabriela Bolzan; Vanessa Bielefeldt Leotti; Camila Maria de Oliveira; Gabriela Ecco; Amanda Henz Cappelli; Anastacia Guimarães Rocha; Nathalia Kersting; Mariana Rieck; Lucas Schenatto de Sena; Ana Carolina Martins; Maria-Luiza Saraiva-Pereira; Laura Bannach Jardim
Journal:  Cerebellum       Date:  2021-07-06       Impact factor: 3.847

10.  Autosomal dominant hereditary ataxia in Sri Lanka.

Authors:  Dulika S Sumathipala; Gayan S Abeysekera; Rohan W Jayasekara; Chantal M E Tallaksen; Vajira H W Dissanayake
Journal:  BMC Neurol       Date:  2013-05-01       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.